Report #2827333

Received Feb 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	UNK	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Received 2nd Dose 2 1/2 Weeks Early; Initial report received on 31-Jan-2025. A pharmacist reported that a patient (age, gender, race, ethnicity not reported) received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization early. No medical history or concomitant medications were reported. On an unknown date, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, route, and site not available)]. On an unknown date, 17 days after having been vaccinated with the first dose of HEPLISAV-B, the patient received the second dose of HEPLISAV-B (lot #, expiration date, route, and site not available). The patient received the second dose two and a half weeks too early. No additional information was reported. Company Comment:The company assessed the event as non-serious; Sender's Comments: The company assessed the event as non-serious